TRAIL Polyclonal Antibody

Confirm delete?

Zoom

Cat No: 160750

TNF-related apoptosis-inducing ligand (TRAIL) is a protein encoded by the TNFSF10 gene in humans and is a member of the TNF superfamily of proteins.{52585} TRAIL contains an N-terminal cytoplasmic domain, a transmembrane domain, and a C-terminal extra...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

apoptosis cell death TNF DR4 DR5 NF-.kappa.B NF-kappab NF-kappab antisera antiserum antibodies WB western blots blotting cancers immunoblotting CD-253 DcR-1 2 DR-4 5 Apo2L Apo2

Product Overview:
TNF-related apoptosis-inducing ligand (TRAIL) is a protein encoded by the TNFSF10 gene in humans and is a member of the TNF superfamily of proteins.{52585} TRAIL contains an N-terminal cytoplasmic domain, a transmembrane domain, and a C-terminal extracellular receptor binding domain.{52585,52586} It is produced in immune effector cells as a transmembrane precursor protein from which mature, soluble TRAIL is formed by proteolysis.{52586} Soluble TRAIL is cleaved from the precursor protein on the extracellular side of the membrane in response to stimulation by cytokines, such as IFN-γ (Item No. 32008).{52585} TRAIL monomers form trimers with a single zinc atom bound at the trimer interface, which is required for its structural stability and function.{52587} The trimer binds to the pro-apoptotic death receptors DR4 and DR5 and the decoy receptors DcR1 and DcR2, which lack functional intracellular domains.{52585} The intracellular death domains of DR4 or DR5 colocalize upon TRAIL binding, which recruits Fas-associated death domain (FADD) and pro-caspase-8 and initiates either the extrinsic or intrinsic apoptotic pathways depending on the cell type. DR4 and DR5 are highly expressed on a variety of cancer cells while DcR1 and DcR1 are primarily expressed on non-cancerous cells, which allows TRAIL to selectively induce apoptosis in cancer cells.{52588} Recombinant human TRAIL induces apoptosis in a variety of cancer cell lines and reduces tumor growth in mouse xenograft models.{52589} However, it increases proliferation in certain cancer cells in vitro, and other cells lines develop resistance, which can sometimes be partially mitigated by combining it with other agents. A cysteine-to-threonine mutation at position 723 of TNFSF10 is associated with sporadic breast cancer, and SNPS in TNFSF10 are associated with fatty liver disease, multiple sclerosis, and asthma.{52585} TNFSF10 expression is decreased in breast cancer patients with brain metastases and increased in patients with multiple sclerosis. In addition, protein levels of TRAIL are increased in patients with systemic lupus erythematous (SLE) and multiple sclerosis. Cayman’s TRAIL Polyclonal Antibody can be used for Western blot (WB) applications. The antibody recognizes TRAIL at approximately 35 kDa from human samples.

Size	500 µl
Shipping	wet ice
Host	Rabbit
Antigen	Synthetic peptide from an internal region of human TRAIL
Application(s)	WB
Formulation	500 µl of peptide affinity-purified polyclonal antibody
Custom Code	3822.19
UNSPSC code	12352203

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.